Josh Rothman focuses on patent and trade secret law in the pharmaceutical, biotechnology, and medical device arenas. Josh litigates complex cases for both the patentee and accused infringer. He also counsels clients on mergers and acquisitions due diligence, licensing, and other transactional matters. He has significant experience litigating Hatch-Waxman cases, from pre-lawsuit through appeal, involving blockbuster drugs, such as Prilosec®, Accupril®, Imitrex®, Benicar®, and Sensipar®, including patents covering chemical compounds, polymorphs, enantiomers, salt and solvate forms, solid and sterile formulations, and methods of use and treatment.